These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22542250)

  • 21. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of response to first-line chemotherapy and of the primary lesion in Hodgkin lymphoma].
    Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Gombolevskiĭ VA; Golub SV; Evstikheev ÉV
    Vopr Onkol; 2012; 58(1):66-70. PubMed ID: 22629831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
    Diehl V; Engert A
    Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
    [No Abstract]   [Full Text] [Related]  

  • 27. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
    Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
    Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
    Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V; Fuchs M;
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
    Bröckelmann PJ; Müller H; Guhl T; Behringer K; Fuchs M; Moccia AA; Rank A; Soekler M; Vieler T; Pabst T; Baues C; von Tresckow B; Borchmann P; Engert A
    J Clin Oncol; 2021 Jan; 39(2):107-115. PubMed ID: 33058716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
    J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk, cure and complications in advanced hodgkin disease.
    Horning SJ
    Hematology Am Soc Hematol Educ Program; 2007; ():197-203. PubMed ID: 18024630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
    Gallamini A; Kostakoglu L
    Ann Oncol; 2015 Jun; 26(6):1045-1047. PubMed ID: 26003616
    [No Abstract]   [Full Text] [Related]  

  • 39. Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
    Bröckelmann PJ; Sasse S; Engert A
    Blood; 2018 Apr; 131(15):1666-1678. PubMed ID: 29500174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.